Keros Therapeutics Narrows Losses as Phase 2 Trial for Duchenne Muscular Dystrophy Begins — Keros Therapeutics, Inc.

Event summary

Keros reported a net loss of $28.7M in Q2 2026, down from $30.7M in Q2 2025 due to reduced R&D and restructuring.
Phase 2 trial for rinvatercept in Duchenne muscular dystrophy (DMD) initiated, following promising Phase 1 results showing increased muscle mass and bone density.
Cash position stands at $257.6M as of June 30, 2026, expected to last into the first half of 2028.
R&D expenses dropped by $21.2M YoY due to transitioning elritercept-related costs to Takeda and prior restructuring.

The big picture

Keros Therapeutics is narrowing its losses while advancing its lead candidate, rinvatercept, into Phase 2 trials for DMD. The company's financial discipline—driven by cost reductions and restructuring—positions it to sustain operations through mid-2028. However, its success hinges on the clinical and commercial potential of its TGF-β-targeting pipeline in a competitive biotech landscape.

What we're watching

Clinical Progress: Whether rinvatercept's Phase 2 trial will validate its potential as a disease-modifying treatment for DMD, given the promising Phase 1 data.
Financial Runway: The pace at which Keros burns through its $257.6M cash reserve and whether it can extend runway beyond H1 2028 without additional funding.
Partnership Dynamics: How the transition of elritercept-related costs to Takeda will impact Keros' long-term revenue streams and strategic focus.